Prediction of prostate cancer recurrence after radiotherapy using a fused machine learning approach: Utilizing radiomics from pretreatment T2W MRI images with clinical and pathological information.

IF 1.3 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Negin Piran Nanekaran, Tony H Felefly, Nicola Schieda, Scott C Morgan, Richa Mittal, Eran Ukwatta
{"title":"Prediction of prostate cancer recurrence after radiotherapy using a fused machine learning approach: Utilizing radiomics from pretreatment T2W MRI images with clinical and pathological information.","authors":"Negin Piran Nanekaran, Tony H Felefly, Nicola Schieda, Scott C Morgan, Richa Mittal, Eran Ukwatta","doi":"10.1088/2057-1976/ad8201","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The risk of biochemical recurrence (BCR) after radiotherapy for localized prostate cancer (PCa) varies widely within standard risk groups. There is a need for low-cost tools to more robustly predict recurrence and personalize therapy. Radiomic features from pretreatment MRI show potential as noninvasive biomarkers for BCR prediction. However, previous research has not fully combined radiomics with clinical and pathological data to predict BCR in PCa patients following radiotherapy.&#xD;Purpose: This study aims to predict 5-year BCR using radiomics from pretreatment T2W MRI and clinical-pathological data in PCa patients treated with radiation therapy, and to develop a unified model compatible with both 1.5T and 3T MRI scanners.&#xD;Methods: A total of 150 T2W scans and clinical parameters were preprocessed. Of these, 120 cases were used for training and validation, and 30 for testing. Four distinct machine learning models were developed: Model 1 used radiomics, Model 2 used clinical and pathological data, and Model 3 combined these using late fusion. Model 4 integrated radiomic and clinical-pathological data using early fusion.&#xD;Results: Model 1 achieved an AUC of 0.73, while Model 2 had an AUC of 0.64 for predicting outcomes in 30 new test cases. Model 3, using late fusion, had an AUC of 0.69. Early fusion models showed strong potential, with Model 4 reaching an AUC of 0.84, highlighting the effectiveness of the early fusion model.&#xD;Conclusions: This study is the first to use a fusion technique for predicting BCR in PCa patients following radiotherapy, utilizing pre-treatment T2W MRI images and clinical-pathological data. The methodology improves predictive accuracy by fusing radiomics with clinical-pathological information, even with a relatively small dataset, and introduces the first unified model for both 1.5T and 3T MRI images.</p>","PeriodicalId":8896,"journal":{"name":"Biomedical Physics & Engineering Express","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Physics & Engineering Express","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1088/2057-1976/ad8201","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The risk of biochemical recurrence (BCR) after radiotherapy for localized prostate cancer (PCa) varies widely within standard risk groups. There is a need for low-cost tools to more robustly predict recurrence and personalize therapy. Radiomic features from pretreatment MRI show potential as noninvasive biomarkers for BCR prediction. However, previous research has not fully combined radiomics with clinical and pathological data to predict BCR in PCa patients following radiotherapy. Purpose: This study aims to predict 5-year BCR using radiomics from pretreatment T2W MRI and clinical-pathological data in PCa patients treated with radiation therapy, and to develop a unified model compatible with both 1.5T and 3T MRI scanners. Methods: A total of 150 T2W scans and clinical parameters were preprocessed. Of these, 120 cases were used for training and validation, and 30 for testing. Four distinct machine learning models were developed: Model 1 used radiomics, Model 2 used clinical and pathological data, and Model 3 combined these using late fusion. Model 4 integrated radiomic and clinical-pathological data using early fusion. Results: Model 1 achieved an AUC of 0.73, while Model 2 had an AUC of 0.64 for predicting outcomes in 30 new test cases. Model 3, using late fusion, had an AUC of 0.69. Early fusion models showed strong potential, with Model 4 reaching an AUC of 0.84, highlighting the effectiveness of the early fusion model. Conclusions: This study is the first to use a fusion technique for predicting BCR in PCa patients following radiotherapy, utilizing pre-treatment T2W MRI images and clinical-pathological data. The methodology improves predictive accuracy by fusing radiomics with clinical-pathological information, even with a relatively small dataset, and introduces the first unified model for both 1.5T and 3T MRI images.

利用融合机器学习方法预测前列腺癌放疗后的复发:从治疗前的 T2W MRI 图像中利用放射组学与临床和病理信息。
背景:局部前列腺癌(PCa)放疗后的生化复发(BCR)风险在标准风险组中差异很大。我们需要低成本的工具来更准确地预测复发并进行个性化治疗。治疗前核磁共振成像的放射组学特征显示出作为无创生物标记物预测 BCR 的潜力。 目的:本研究旨在利用放疗前 T2W 磁共振成像的放射组学特征和临床病理数据预测接受放疗的 PCa 患者的 5 年 BCR,并建立一个与 1.5T 和 3T 磁共振成像扫描仪兼容的统一模型:预处理共 150 个 T2W 扫描和临床参数。其中 120 例用于训练和验证,30 例用于测试。开发了四种不同的机器学习模型:模型 1 使用放射组学,模型 2 使用临床和病理数据,模型 3 使用后期融合将这些数据结合起来。模型 4 利用早期融合将放射组学和临床病理学数据整合在一起:模型 1 的 AUC 为 0.73,而模型 2 预测 30 个新测试病例结果的 AUC 为 0.64。使用晚期融合的模型 3 的 AUC 为 0.69。早期融合模型显示出强大的潜力,模型 4 的 AUC 达到 0.84,凸显了早期融合模型的有效性:本研究首次利用治疗前 T2W MRI 图像和临床病理数据,采用融合技术预测放疗后 PCa 患者的 BCR。该方法通过融合放射组学和临床病理学信息,提高了预测准确性,即使数据集相对较小,并首次引入了适用于 1.5T 和 3T MRI 图像的统一模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biomedical Physics & Engineering Express
Biomedical Physics & Engineering Express RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
2.80
自引率
0.00%
发文量
153
期刊介绍: BPEX is an inclusive, international, multidisciplinary journal devoted to publishing new research on any application of physics and/or engineering in medicine and/or biology. Characterized by a broad geographical coverage and a fast-track peer-review process, relevant topics include all aspects of biophysics, medical physics and biomedical engineering. Papers that are almost entirely clinical or biological in their focus are not suitable. The journal has an emphasis on publishing interdisciplinary work and bringing research fields together, encompassing experimental, theoretical and computational work.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信